Abundia Global Impact vs Arcadia Biosciences
AGIG and RKDA side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGIG and RKDA compare
Abundia Global Impact is the larger company, worth 68 times as much as Arcadia Biosciences ($35.8M against $525K).
Abundia Global Impact grew revenue faster over the last twelve months (101% versus −2.1% for Arcadia Biosciences).
Arcadia Biosciences keeps more of each dollar of sales as profit, with a net margin of −202% compared with −386% at Abundia Global Impact.
Arcadia Biosciences scores higher on the StockData Score (7 against 2 for Abundia Global Impact), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGIG | RKDA |
|---|---|---|
| Size and price | ||
| Market cap | $35.8M | $525K |
| Share price | $0.810 | $0.218 |
| Change, 1 year | −84.9% | −93.9% |
| Change, 5 years | −95.2% | −99.7% |
| Beta (5Y) | −0.35 | 1.05 |
| Employees | 2 | 8 |
| StockData Score | ||
| Total score | 2 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.8× | 0.1× (better) |
| FCF yield | −55.0% | – |
| Growth | ||
| Revenue growth (TTM) | 101% (better) | −2.1% |
| Revenue growth, 5Y average | −5.8% (better) | −9.6% |
| Profitability | ||
| Gross margin | – | 41.1% |
| Operating margin | −356% | −68.9% (better) |
| Net margin | −386% | −202% (better) |
| FCF margin | −428% | – |
| Return on equity | −109% | – |
| Return on invested capital | −49.8% | – |
| Financial health | ||
| Interest coverage | −72.5× | – |
| Current ratio | 0.35 | 3.58 (better) |
| Altman Z-score | −2.17 (better) | −86.52 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 5.9% | 8.8% |
| Held by insiders | 73.0% | 1.4% |
| Insider net buying, 12 months | $276K | – |
| Short interest, % of float | 2.9% | 4.9% |
Go deeper
- AGIG stock overview
- AGIG income statement
- AGIG valuation and score
- RKDA stock overview
- RKDA income statement
- RKDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.